In addition to substantial price reduction, Eli Lilly said it would launch on April 1 a new insulin product called Rezvoglar — a copycat version of Sanofi’s Lantus insulin.

New Delhi: There is excitement and hope in the insulin market the world over after U.S. based pharma giant Eli Lilly & Company on Monday announced results of its “successful” late-stage trial ...

Drugmaker Eli Lilly says it will cut its insulin prices up to 70% and cap out-of-pocket costs for privately insured consumers at $35 a month.

Eli Lilly CEO says insulin tweet flap “probably” signals need to bring down cost "We’re obviously not the only insulin company. But the tropes go on," he said.

With FDA clearance secured for its Bluetooth-connected insulin dose-tracking technology, Eli Lilly is ready to pick up the tempo.

Positive preliminary results for Eli Lilly’s efsitora alfa continue to build the case for this once-weekly insulin in type 2 diabetes patients. Lilly is trying to catch up to Novo Nordisk’s ...

Eli Lilly and Company (NYSE:LLY) is one of the 10 Best Non-Tech Stocks to Buy and Hold For 3 Years. On June 22, Eli Lilly and ...

As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will leave them in the lurch.

Eli Lilly will cut prices for some older insulins later this year and immediately expand a cap on costs insured patients pay to fill prescriptions. Lilly said it will cut the list price for its ...

Eli Lilly (LLY) stock will be in focus as two phase 3 trials for its once-weekly insulin efsitora alfa succeed against daily basal insulins. Read more here.